Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.

Scroll through any hoops-heavy feed on X, and you’ll see it. The post Our Fans Approve Blockbuster All-Star in Indy, But All ...